Abstract

ApoC-III overexpression in mice results in severe hypertriglyceridemia due primarily to a delay in the clearance of triglyceride-rich lipoproteins. We have, in primary cultures of rat hepatocytes, characterized a lipolysis-stimulated receptor (LSR). The apparent number of LSR that are available on rat liver plasma membranes is negatively correlated with plasma triglyceride concentrations measured in the fed state. We therefore proposed that the primary physiological role of the LSR is to contribute to the cellular uptake of triglyceride-rich lipoproteins. We have now tested the effect of apoC-III on the binding of triglyceride-rich lipoproteins to LSR. Supplementation of 125I-very low density lipoprotein (VLDL) with apoC-III inhibited the LSR-mediated binding, internalization, and degradation of 125I-VLDL in primary cultures of rat hepatocytes. Studies using isolated rat liver plasma membranes showed that enrichment of human VLDL and chylomicrons with synthetic or purified human apoC-III decreased their binding to the LSR by about 40%. Supplementation of triglyceride-rich lipoproteins under the same conditions with human apoC-II had no such inhibitory effect, despite the fact that this apoprotein bound as efficiently as apoC-III to these particles. Preincubation of LDL with apoC-III did not modify its binding to LSR. Partitioning studies using 125I-apoC-III showed that this lack of effect was due to apoC-III's inability to efficiently associate with LDL. Purified human apoC-III1 was as efficient as the synthetic nonsialylated form of apoC-III in inhibiting binding of VLDL to LSR. However, despite a 2-fold greater binding of apoC-III2 to VLDL, this isoform was a less efficient inhibitor of the binding of VLDL to LSR than apoC-III1 or nonsialylated apoC-III. Desialylation of apoC-III2 by treatment with neuraminidase increased the inhibition of VLDL binding to LSR to a level similar to that observed with apoC-III1 and nonsialylated apoC-III. We propose that apoC-III regulates in part the rate of removal of triglyceride-rich particles by inhibiting their binding to the LSR, and that the level of inhibition is determined by the degree of apoC-III sialylation.

Highlights

  • Preincubation of low density lipoprotein (LDL) with apoC-III did not modify its binding to lipolysis-stimulated receptor (LSR)

  • ApoE has been shown to mediate the binding of triglyceride-rich lipoproteins (TGRL) to heparan sulfate proteoglycans, and it was recently reported that the very low density lipoprotein (VLDL) isolated from apoC-III overexpressors were defective in binding to heparin-Sepharose, suggesting that the excess apoC-III inhibits their binding to heparan sulfate proteoglycans on endothelial cells [19]

  • We first tested the effect of apoC-III on the binding to LSR of the different lipoprotein fractions that had previously been identified as potential ligands for this candidate receptor [23, 24]

Read more

Summary

Introduction

Preincubation of LDL with apoC-III did not modify its binding to LSR. Partitioning studies using 125I-apoC-III showed that this lack of effect was due to apoC-III’s inability to efficiently associate with LDL. In subjects with normal plasma lipid levels, 30% of apoC-III is distributed among triglyceride-rich lipoproteins (TGRL), i.e. chylomicrons and very low density lipoprotein (VLDL), and about 60% is bound to high density lipoprotein [1]. Because most of the plasma lipolytic enzymes, i.e. lipoprotein and hepatic lipases, are bound to heparan sulfate proteoglycans, this docking defect of apoC-III-enriched TGRL could subsequently reduce the rate of lipolysis. ApoCIII has been shown to decrease the binding of VLDL to the low density lipoprotein (LDL)-receptor expressed in human fibroblasts [20, 21]. This inhibitory effect was observed with apoC-III, and with apoC-I and C-II, apoC-I being the most effective. ApoC-I, but not apoC-III, inhibits the binding of apoE-enriched ␤-VLDL to the LDL-receptor related protein (LRP) [22]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.